---All---
  • ---All---
  • Accession
  • Catalog #

APG4D Antibody (N-term) Blocking PeptideSynthetic peptide

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
BP1811a 0.1 mg 400 ul In Stock $ 45.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

APG4D Antibody (N-term) Blocking Peptide - Product info

Primary AccessionQ86TL0
Clone Names5011805
Calculated MW52922 Da

APG4D Antibody (N-term) Blocking Peptide - Additional info

Gene ID 84971
Target/Specificity
The synthetic peptide sequence used to generate the antibody AP1811a was selected from the N-term region of human Autophagy APG4D. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Format
The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.
Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

APG4D Antibody (N-term) Blocking Peptide - Protein Information

Name ATG4D
Synonyms APG4D, AUTL4
Function
Cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes
Cellular Location
Cytoplasm (Probable).
Tissue Location
Mainly expressed in skeletal muscle and, to a lower extent, in testis

APG4D Antibody (N-term) Blocking Peptide - Related products

AM1896a: ATG4D antibody (Ascites)

AM1896b: ATG4D Antibody

AP11448a: ATG4D Antibody (N-term)

AP1811a: ATG4D Antibody (N-term)

AP1811b: ATG4D Antibody (Center)

AP1811c: ATG4D Antibody (C-term)

AP1811e: ATG4D Antibody (C-term)

AP1811f: ATG4D Antibody (center)

AP1811l: ATG4D Antibody

AP3394a: Phospho-ATG4D-S15 Antibody

AP3395a: Phospho-ATG4D-S341 Antibody

AP3395b: Phospho-ATG4D-S467 Antibody

RI10457: ATG4D predesign siRNA

BP1811a: APG4D Antibody (N-term) Blocking Peptide

BP1811b: APG4D Antibody (Center) Blocking Peptide

BP1811c: APG4D Antibody (C-term) Blocking Peptide

BP1811e: APG4D Antibody (C-term) Blocking Peptide

BP1811f: ATG4D Antibody (center) Blocking Peptide

BP3394a: Phospho-APG4D-S15 Antibody Blocking Peptide

BP3395a: Phospho-APG4D-S341 Antibody Blocking Peptide

BP3395b: Phospho-APG4D-S467 Antibody Blocking Peptide

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Macroautophagy is the major inducible pathway for the general turnover of cytoplasmic constituents in eukaryotic cells, it is also responsible for the degradation of active cytoplasmic enzymes and organelles during nutrient starvation. Macroautophagy involves the formation of double-membrane bound autophagosomes which enclose the cytoplasmic constituent targeted for degradation in a membrane bound structure, which then fuse with the lysosome (or vacuole) releasing a single-membrane bound autophagic bodies which are then degraded within the lysosome (or vacuole). APG4 is a cysteine protease required for autophagy, which cleaves the C-terminal part of either MAP1LC3, GABARAPL2 or GABARAP, allowing the liberation of form I. A subpopulation of form I is subsequently converted to a smaller form (form II). Form II, with a revealed C-terminal glycine, is considered to be the phosphatidylethanolamine (PE)-conjugated form, and has the capacity for the binding to autophagosomes.

REFERENCES

Baehrecke EH. Nat Rev Mol Cell Biol. 6(6):505-10. (2005) Lum JJ, et al. Nat Rev Mol Cell Biol. 6(6):439-48. (2005) Greenberg JT. Dev Cell. 8(6):799-801. (2005) Levine B. Cell. 120(2):159-62. (2005) Shintani T and Klionsky DJ. Science. 306(5698):990-5. (2004)